- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00472342
The Effects of Exercise on Adipokine in Impaired Fasting Glucose or Impaired Glucose Tolerance Patients
Many adipokines are thought that related with metabolic disturbance such as glucose intolerance, dyslipidemia, and insulin resistance. It is reported that regular physical training could prevent the progression of diabetes from prediabetes and improve the insulin resistance. After physical training, many adipokine levels were changed due to improving insulin resistance.
In this study, we will examine the various adipokine levels such as adiponectin, RBP-4, and adrenomedullin after exercise training through exercise prescription in IFG and IGT patients.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Backgrounds: Type 2 diabetes mellitus can be caused by genetic and environmental factors. Type 2 diabetes could be prevented by modifying the environmental risk factors such as physical inactivity, heavy eating, and obesity. It is reported that regular physical training could prevent the progression of diabetes from prediabetes such as impaired glucose tolerance (IGT) and impaired fasting glucose (IFG).
Prediabetes, the term of IGT and IFG, could progress to type 2 diabetes in 30~40 % within 4~5 years. Moreover, cardiovascular and cerebrovascular events are increased in prediabetic patients like as type 2 diabetic patients.
Adipose tissue is thought as a endocrine organ that secrets and regulates various hormones known as adipokines including adiponectin, resistin, leptin, visfatin, tumor necrosis factor (TNF)-α, interleukin-6 (IL-6), and retinol-binding protein 4 (RBP 4). Recently, many adipokines are thought that related with metabolic disturbance such as glucose intolerance, dyslipidemia, and insulin resistance.
Adiponectin is known as anti-diabetic factor exerting actions on muscle fatty acid oxidation and insulin sensitivity. Plasma adiponectin levels are significantly decreased in obese, type 2 diabetes, and insulin resistant patients and correlated with insulin sensitivity. Also, adiponectin has anti-inflammatory and anti-atherogenic effects. So, adiponectin is representative insulin sensitivity marker and may be a protective factor against development of type diabetes. In previous data, there was discrepancy in effects of exercise on adiponectin levels. Some study showed exercise interventions could not have effects on adiponectin levels. However, other study suggested that physical fitness may increase adiponectin levels in obese insulin resistant adults.
RBP-4, secreted by adiocytes, has effects on reducing glucose transporter 4 (GLUT 4) in adipocytes or increasing gluconeogenesis enzyme activity such as PEPCK in the liver. Also, it is known that RBP-4 is elevated in insulin resistant patients such as type 2 diabetes and obesity. After exercise training, RBP-4 levels were decreased in subjects with improvements of insulin resistance.
Adrenomedullin (AM), originally isolated in pheochromocytoma, is recently reported as adipokine. AM is highly expressed in adipocyte of high fat diet mice or obese rat model and elevated in type 2 diabetic patients. Also, AM expression on white and brown adipose tissue was increased after adrenergic stimulation. So, it is expected that AM expression will be changed by exercise.
In this study, we will examine the various adipokine levels such as adiponectin, RBP-4, and adrenomedullin after exercise training through exercise prescription in IFG and IGT patients.
Methods
Subjects Subjects having IFG and IGT on the basis of a 75g oral glucose tolerance test (OGTT) according to American Diabetes Association criteria will be studied.
Inclusion Criteria
- Age; 30~70
- Subjects with IGT and IFG
- Subjects with having possibility of exercise stress test
- Subjects with having a strong will to this study
Exclusion Criteria
- Age <30 or >70
- Cr more than 1.5 mg/dL
- AST, ALT levels more than twice as upper normal range
- Subjects having past history of coronary artery disease
Study design
- Study design - before and after methods
- Visit time - baseline, after 3months, after 6months
- 1st visit- IGT and IFG diagnosis by 75g OGTT fill up the agreement Lab sampling
- 2nd visit - exercise stress test exercise prescription by physician follow wup lab sampling
- 3rd visit - follow up lab sampling completing the study
- Dietary pattern data - FFQ and 3 day dietary recall Baseline - FFQ and 3 day dietary recall 2nd visit - 3 day dietary recall 3rd visit - 3 day dietary recall After 1 year - FFQ
- Exercise pattern data - International Physical Activity Questionnaire (IPAQ)
1st, 2nd, and 3rd visits- IPAQ 8) We will compare the parameters according to results of IPAQ (by tertile) 9) We will adjust the parameters by dietary pattern 10) Anthropometric measurements
- Height, weight, BMI, waist circumference, hip circumference 11) Exercise capacity - exercise tolerance test and Vmax O2 12) Biochemical markers
- Glucose, HbA1C, WBC, AST, ALT, GGT, total cholesterol, triglyceride, HDL cholesterol, insulin, C-peptide 13) Adipokine
- adiponectine, RBP-4, adrenomedullin 14) Insulin resistance marker
- HOMA-IR 15) Inflammatory marker
- C-reactive protein (CRP)
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Choon Hee Chung, Prefessor
- Phone Number: 82-33-741-0506
- Email: cchung@yonsei.ac.kr
Study Locations
-
-
Kangwon-Do
-
Wonju, Kangwon-Do, Korea, Republic of, 220-701
- Recruiting
- Mi Young Lee
-
Contact:
- Mi Young Lee, Dr
- Phone Number: 82-33-741-0681
- Email: domoe46@yonsei.ac.kr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age; 30~70
- Subjects with IGT and IFG
- Subjects with having possibility of exercise stress test
- Subjects with having a strong will to this study
Exclusion Criteria:
- Age <30 or >70
- Cr more than 1.5 mg/dL
- AST, ALT levels more than twice as upper normal range
- Subjects having past history of coronary artery disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Improvements of adipokine levels
Time Frame: 6 Months
|
6 Months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Prevention of diabetes
Time Frame: 1~5 year
|
1~5 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mi Young Lee, Dr, Department of Internal Medicine, Yonsei University Wonju College of Medicine
- Study Chair: Choon Hee Chung, professor, Department of Internal Medicine, Yonsei Univerisity Wonju College of Medicine
Study record dates
Study Major Dates
Study Start
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- kenshin46
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
Oregon State UniversitySanofiCompletedType I or Type II Diabetes (Excludes Gestational Diabetes)
-
Taichung Veterans General HospitalNational Health Research Institutes, TaiwanRecruitingDiabetes Complications | Type 2 Diabetes | Maturity-Onset Diabetes of the Young (MODY)Taiwan
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
University of RoehamptonRecruitingType2 Diabetes Mellitus | Pre DiabetesUnited Kingdom
Clinical Trials on exercise prescription
-
Peking University People's HospitalNot yet recruiting
-
Royal Cornwall Hospitals TrustRecruitingBariatric Surgery | PrehabilitationUnited Kingdom
-
Jing MaNot yet recruitingCoronary Heart DiseaseChina
-
Endocrinology and Clinical Nutrition Research Center...UnknownFrail Elderly Syndrome | SarcopeniaSpain
-
Dartmouth-Hitchcock Medical CenterNational Cancer Institute (NCI)Recruiting
-
Baylor Research InstituteSports AcademyRecruitingCOVID-19United States
-
The Cleveland ClinicBrentwood FoundationCompletedObesity | Physical ActivityUnited States
-
Ottawa Hospital Research InstituteCanadian Institutes of Health Research (CIHR)Recruiting
-
University Hospital, CaenCompletedPhysical Activity | Chronic Disease | PrescriptionFrance
-
University at BuffaloNational Center for Advancing Translational Sciences (NCATS)CompletedBrain Injury | ConcussionUnited States